This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in
which IMT-009 will be administered by the intravenous (IV) route to participants with solid
tumors or lymphomas.
The main goals of this study are to:
Find the recommended dose of IMT-009 that can be safely given to participants
Learn more about the side effects of IMT-009
Learn more about pharmacokinetics of IMT-009
Learn more about the effectiveness of IMT-009
Learn more about different pharmacokinetic biomarkers and how they might change in the
presence of IMT-009
IMT-009 is an Fc-attenuated monoclonal antibody that binds with high affinity and selectivity
to CD161, a receptor that is broadly expressed on NK and a subset of memory T cells, blocking
interactions between the receptor and its cognate ligand, CLEC2D, which is expressed on the
surface of both cancer cells and immune cells. Preclinical data confirm that CD161 blockade
with IMT-009 results in enhanced anti-tumor activity. This is a Phase 1/2a, open label dose
escalation study of IMT-009, a fully human monoclonal antibody targeting CD161, given as a
single agent in Phase 1 and potentially in combination with other antineoplastic agents in
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, T-cell Lymphoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.